===Moderna (MRNA): Phase 3 melanoma mRNA therapy success with Merck (MRK)

Moderna (MRNA +142%) and Merck (MRK +11.3%) announced this morning that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its primary and key secondary endpoints in high-risk melanoma.

Merck and Moderna Phase 3 INTerpath-001 topline data show V940 plus Keytruda met primary and key secondary endpoints in melanoma

• Trial enrolled patients with completely resected Stage IIB-IV melanoma receiving adjuvant intismeran autogene (V940) plus KEYTRUDA
• Merck and Moderna plan to engage regulators on filing submissions for the V940 and KEYTRUDA combination regimen

• The combination is the first and only regimen to demonstrate statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone in this setting.

• The readout also marks the first positive Phase 3 trial for an individualized neoantigen therapy and an mRNA-based cancer therapy, providing major validation for Moderna's mRNA platform beyond infectious disease and potentially opening a meaningful new opportunity in oncology. As a result, MRNA shares are surging on the results.

• The results are supporting broader enthusiasm around precision medicine, computational biology and personalized therapeutics, with the landmark Phase 3 readout providing an important clinical proof point for highly individualized treatment approaches.

• Precision medicine and next-generation biotech names trading higher include Tempus AI (TEM +22.2%), BioNTech (BNTX +20.4%), Ginkgo Bioworks (DNA +15.3%), Prime Medicine (PRME +13.4%), Recursion Pharmaceuticals (RXRX +9.6%).

Earnings this week : Aug 17 - 21, 26 (wk 34)

 

Monday (August 17)

• Morning: AGPU, CRGO, FUFU, HTHT, NSPR
• Afternoon: FN, DCGO, FLXS, FN, XP, YALA

Tuesday (August 18)

• Morning: AS BIDU CAAP ELTK ELWT ENRD EVGN HSAI IQ HD KLAR PONY PRE RNW THCH UCL VNET 
• Afternoon: JKHY KEYS LZB MRCY TOL ZTO

Wednesday (August 19)

• Morning: ADI EL KC LOW TGT TJX VIK
• Afternoon: BILL COTY NDSN BULL WOLF

Thursday (August 20)

• Morning: AAP BABA ATHM NTES SCSC WMT DE
• Afternoon: FLO OSIS ROST

Friday (August 21)

• Morning: BJ BKE
• Afternoon: None

This week's biggest % gainers & losers : Aug 10 - 14, 26 (wk 33)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: INO (1.09 +62.43%), STIM (3.20 +34.24%), OMER (17.26 +30.26%), CERS (2.95 +25.53%), ACB (3.66 +22.41%), ASMB (32.40 +21.44%), EVH (4.73 +19.62%)

• Industrials: CSTE (3.42 +48.7%), ATRO (93.83 +20.68%)

• Consumer Discretionary: HZO (52.11 +46.05%), RRGB (10.25 +25%)

• Information Technology: PSTG (116.99 +29.91%), STX (962.83 +18.46%), CAMP (5.01 +18.16%)

• Energy: PARR (80.36 +21.22%), HP (44.26 +19.3%), MPC (354.48 +18.87%)

This week's top % losers

• Healthcare: ABEO (5.88 -18.78%), TCMD (24.07 -18.41%)

• Materials: ACH (1.01 -63.93%), BAK (1.95 -15.07%)

• Industrials: REZI (20.36 -21.93%), ACM (62.59 -17.47%), HUBG (40.2 -15.9%)

• Consumer Discretionary: TPR (129.49 -20.25%), EYE (19.16 -15.06%), GRPN (21.3 -14.9%), SFIX (3.58 -14.88%)

• Information Technology: MB (5.47 -38.68%), SPWR (0.22 -18.26%), CEVA (32.85 -15.05%), COHR (325.4 -14.17%)

• Energy: KLXE (1.69 -17.96%)

===Figure Technology Solutions (FIGR) reported earnings on Thur 13 Aug 2026 (b/o)

 

Figure Technology Solutions Q2 2026 non-GAAP EPS $0.35 (+150% YoY) and revenue $225.6M (+102% YoY) beat estimates as Connect mix boosts margins

• Investor Takeaway: Strong volume and revenue beat with expanding margins as capital-light Connect scales rapidly.
• Biggest Positive: Figure Connect now 65% of volume, driving 55% adjusted EBITDA margin and capital efficiency.
• Biggest Risk: Take rate at 3.6% pressured by faster-than-expected mix shift and rate volatility.
• Key Results: $4.3B CLM volume (+132% YoY, 4% above guidance top), $218M adjusted net revenue (+95%).
• Profitability: Net income $87M (+190% YoY); adjusted EBITDA $119M (+126%), 55% margin despite 1.7-point Democratized Prime drag.
• Guidance: Q3 CLM volume $4.8–5.2B (midpoint $5B); management "feels very strongly confident" based on July seasonality.
• Growth Drivers: HELOC-led demand, new SMB/home improvement verticals, 489 partners (+102 QoQ), Democratized Prime third-party assets $170M.
• Problem Areas: Take rate expected to stay near low end of 3.5–4% range; interest-rate moves hurt gain-on-sale.
• Balance Sheet & Capital: $1.44B cash; $600M 8.5% senior notes fund Kiavi deal and broaden funding access.